

Progress Review Group Primer



Last Updated October 2004

Table of Contents

| Overview | 1 |
|---|----|
| Phase I: The Recommendation Phase | 4 |
| Phase II: The Implementation Phase | 16 |
| Phase III: The Reporting Phase | 21 |
| Conclusion | 26 |
| List of Tables | |
| Table 1. Recommendation Phase Tasks, Participants' Responsibilities, and Timeline | 4 |
| Table 2. Planning Meeting Preparations | |
| Table 3. Planning Meeting Roles/Responsibilities | 9 |
| Table 4. Roundtable Meeting Preparations | 11 |
| Table 5. Roundtable Meeting Roles/Responsibilities | 13 |
| Table 6. Implementation Phase Tasks, Participants' Responsibilities, and Timeline | 16 |
| Table 7. Response Meeting Roles/Responsibilities | 19 |
| Table 8. Potential Implementation Strategy Scheme | |
| Table 9. Reporting Phase Tasks, Participants' Responsibilities, and Timeline | 21 |
| List of Figures | |
| Figure 1. The PRG Process | 3 |
| Figure 2. Sample Planning Meeting Agenda | 8 |
| Figure 3. Sample Roundtable Meeting Agenda | 12 |
| Figure 4. Sample Tables of Contents for PRG Reports | 15 |
| Figure 5. Sample Progress Report Table of Contents | 24 |

Overview

Our nation faces a formidable challenge—to control and eliminate disease. Ongoing research efforts have laid the groundwork to address this challenge. However, with the fast-paced flow of innovative thinking and research discoveries, a need has arisen to chart the course and develop plans to hasten progress. Funding agencies are faced with the responsibility of addressing these needs and identifying clear scientific priorities in an effort to capitalize on recent scientific discoveries and opportunities, provide guidance, and create benchmarks against which progress can be measured. Progress Review Groups (PRGs) represent one mechanism to do just that assess the state of the science for a particular disease or group of related diseases, identify research gaps and resource needs, and generate recommendations for future research that could guide the field over the next 5 to 10 years. The PRG process entails a comprehensive, collaborative, and integrated approach with three phases: (1) developing recommendations with input from clinical, research, and advocacy communities; (2) planning for and implementing strategies to achieve scientific advances based on PRG recommendations; (3) reporting on progress made in addressing PRG recommendations. Thus, the PRG process can continually evaluate progress by tracking current and future research trends and can provide a framework for a national effort to control and eliminate disease.

Overview

PRG Charge Example

- → Identify and prioritize scientific research opportunities and needs to advance medical progress against the disease focus and describe the scientific resources required to address these opportunities and needs.
- → Compare and contrast these priorities with the sponsoring agency's research portfolio.
- → Prepare a written report that describes recommendations for meeting opportunities and needs.
- → Discuss a plan of action with the sponsoring agency leaders to ensure that the priority areas are addressed.

This primer is designed to provide both an overview of the PRG process and guidelines for planning and conducting the process. Information included in this primer is based in large part on the 11 PRGs sponsored by the National Cancer Institute (NCI) and implemented by the NCI's Office of Science Planning and Assessment. The NCI PRG website (http://prg.nci.nih.gov/) contains copies of all the reports that have been developed through the PRG process. In combination with this primer, the website can be used as a resource for organizing a PRG.

As a funding agency undertakes this challenge, consideration must be given to the enormous investment in tools and resources that are needed to successfully manage the PRG process, including electronic resources and staffing. After careful consideration, if the funding agency decides that the PRG process is the best means to move research forward, the sponsoring agency's staff may establish a PRG charge (see example) that emphasizes the importance of identifying scientific opportunities, needs, and resources.

<u>Summary of the Process – Three Phases</u>



The PRG process involves individuals both within and outside the sponsoring agency and is conducted in a sequence of three phases: *Recommendation, Implementation,* and *Reporting* (**Figure 1**). Additional details about each of the phases can be found in the corresponding sections of this primer.

The *Recommendation Phase* takes approximately 9 to 12 months to complete. The goal of this phase is to prepare a PRG Report that provides an overview of the state of the science, outlines top research priorities and resources needed to address a given disease, and serves as a benchmark from which progress can be assessed. This report is prepared by the PRG, a panel of 20 to 30 prominent members of the scientific, medical, and advocacy communities. An important element of this phase is the Roundtable meeting, a forum in which the PRG receives additional information from a larger group of 80 to 100 renowned leaders from the scientific and advocacy communities.

Overview 2

WORKING DRAFT



- The *Implementation Phase* takes approximately 9 months to accomplish. The end product of this phase is an Implementation Strategy that delineates approaches, applications, and resources that will be used to successfully implement the proposed PRG recommendations. A working group internal to the sponsoring agency is responsible for developing this plan. Upon approval by the sponsoring agency's leaders, the plan is implemented, promoted, and monitored over the subsequent years.
- The Reporting Phase is initiated 3 to 4 years after the publication of the Implementation Strategy. It consists of an assessment of progress made in addressing the PRG recommendations. This is accomplished through the development of a progress report by the sponsoring agency that summarizes progress and evolving needs.

Phase I Recommendation

- → Appoint PRG Leadership Team.
- → Hold Leadership meeting.
- → Recruit PRG members and prepare for Planning meeting.
- → Hold PRG Planning meeting.
- → Prepare for Roundtable meeting.
- → Hold Roundtable meeting.
- → Prepare PRG Report.
- → Present report to sponsoring agency leaders and release report.

Phase II Implementation

- → Establish internal Working Group.
- → Map agency's initiatives and projects to PRG recommendations.
- → Prepare proposal for implementing PRG recommendations.
- → Hold Pre-Response meeting.
- → Hold Response meeting.
- → Prepare and promote Implementation Strategy.
- → Identify measures of progress.

Figure 1. The PRG Process

Phase III Reporting

- → Reconvene Working Group.
- → Collect and analyze data.
- → Prepare progress report.
- → Discuss progress with sponsoring agency leaders advisors.
- → Make course corrections as needed and adjust Implementation Strategy.

Overview 3

PHASE

The Recommendation Phase

The purpose of the Recommendation Phase is to identify top research priorities and resources needed to advance the field. The tasks for this phase, the participants' responsibilities, and the projected timeline are depicted in **Table 1**. This process involves bringing together prominent members of the scientific, medical, and advocacy communities who evaluate the state of the science, discuss the impediments to progress against the disease, and identify the research and resources needed to drive the field forward. The primary product of this phase is a PRG Report.

Table 1. Recommendation Phase Tasks, Participants' Responsibilities, and Timeline

| Task | Sponsoring Agency Staff | PRG Leadership Team | PRG Members | PRG Roundtable Participants | Approximate Duration |
|---|-------------------------------|---------------------------|----------------|-----------------------------------|-------------------------|
| Appoint PRG Leadership Team. | v + | | | | < 1 month |
| Hold Leadership meeting. | ✓ | ✓ | | | 1/2 day |
| Recruit PRG members and prepare for Planning meeting. | v | V | | | 2 to 3 months |
| Hold PRG Planning meeting. | ✓ | ✓ | ✓ | | 1 to 2 days |
| Prepare for Roundtable meeting. | ✓ | ✓ | | | 2 to 3 months |
| Hold Roundtable meeting. | ✓ | ✓ | ✓ | ✓ | 2 to 3 days |
| Prepare PRG Report. | ✓ | V | ✓ | * | 3 months |
| Present Report to sponsoring agency leaders and release report. | ✓ | V | | | 2-hour meeting/ call |

 $[\]textbf{\textit{+}} \textbf{Sponsoring agency staff supports logistics for appointments that are made by agency leadership. }$

^{*}Some Roundtable participants may contribute to writing portions of the report if his/her expertise is necessary or he/she co-chaired a Breakout Group.

<u>PRG Leadership Team Appointed</u>



The sponsoring agency appoints a Leadership Team composed of an internal agency staff member to serve as Executive Director and two Co-Chairs from the extramural scientific/medical community. The selection of the Leadership Team is critical to the success of the PRG, so each member of the Leadership Team must be a recognized leader in the targeted disease(s) field and have complementary areas of expertise, e.g., basic scientist, clinician, or consumer advocate. The Leadership Team members must not only be able to cover the broad spectrum of the scientific issues, but they must also have the vision and foresight to develop recommendations that are innovative, promising, and attainable. The Leadership Team members must be able to work effectively as a team; have excellent communication, management, and facilitation skills; and be willing and able to make the significant commitment of time and effort required.

An appropriate high-ranking official within the sponsoring agency invites the nominees to serve as PRG Co-Chairs and Executive Director, clearly outlining the roles and responsibilities associated with the appointment. A written invitation letter and information packet follows this oral invitation.

Hold Leadership Meeting

The Leadership meeting is the first gathering of the two PRG Co-Chairs, the Executive Director, and the sponsoring agency leaders. An important task of this meeting is setting dates for conducting the Phase I activities, including conference calls and PRG Planning and Roundtable meetings.

During the Leadership meeting, prominent members of the scientific, medical, and advocacy communities are nominated and tentatively selected, based on their expertise with the targeted disease(s). Consideration is given to adequate disciplinary, institutional, and private sector representation, as well as geographic, gender, and ethnic distribution. A list of potential PRG participants is compiled and prioritized, and 20 to 30 individuals on this list should ultimately be selected.

Recruit PRG Members and Prepare for Planning Meeting

PRG Member Characteristics

- → Expert scientific knowledge (both junior and senior level)
- → Representation from scientific, medical, advocacy, and private sector communities
- → Adequate disciplinary and institutional representation
- → Adequate geographic, gender, and ethnic distribution
- → Team players
- → Commitment, willingness, and time to attend two meetings and contribute to preparing the PRG Report

During this 2- to 3-month interval, two important activities take place: (1) recruiting PRG members and (2) preparing for the Planning meeting.

Recruit PRG Members: PRG members are recruited based on nominations made at the Leadership meeting. The PRG Leadership Team, with assistance from sponsoring agency staff, contacts the nominees and explains the PRG purpose, process, tasks, and time commitment. A written invitation letter and information packet follow this oral invitation. A PRG website and participant database may be useful tools during member recruitment.

<u>Prepare for the Planning Meeting</u>: While recruiting PRG members, the Leadership Team and the sponsoring agency staff prepare for the Planning meeting. Tasks include: (1) assessing the current research, needs, and gaps and (2) addressing Planning meeting logistics.

Current Research, Needs, and Gaps Analyses. An assessment of current research, needs, and gaps can provide a baseline to frame the Planning and Roundtable meeting discussions. The sponsoring agency can use various methods to accomplish this, including: (1) funding analyses, (2) research portfolio analyses, (3) literature reviews or background papers, and (4) concept mapping.

- A funding analysis is a summary of the sponsoring agency's financial investment relevant to the targeted topic. This can be in the form of summary charts showing changes over time, breakdowns by scientific areas, etc. This analysis may be augmented by information from other agencies.
- A research portfolio analysis is a compilation of the current research activity funded by the sponsoring agency. It should include ongoing agency-sponsored research in all areas including basic, clinical, and population-based research. These can be in the form of lists of all research projects, clinical trials, and other activities. If the number of ongoing activities is large, it may be useful to sort the activities into categories. For example, the NCIsponsored portfolio is classified into seven major types of research: biology; etiology; prevention; early detection, diagnosis, and prognosis; treatment; cancer control, survivorship, and outcomes; and scientific model systems.



- Literature reviews or background papers that cover the current state of the science, including peer-reviewed and other relevant scientific publications, and summarize the nature, key issues, and underlying correlates of the disease field.
- Concept mapping is a structured process that enables groups to view relationships among issues, priorities, and subtopics that are considered important. Concept mapping is a multistep process through which a large set of concepts are grouped into a smaller number of clusters. Initially, experts are asked to respond to a specific statement, such as, Complete the following sentence: "Specific actions that should be taken to eliminate this disease are _____."

 A long list of responses is culled down to eliminate duplication and overlap (e.g., 500 responses can be culled to 100). Experts are then asked to group similar statements. By statistically analyzing these results, a short list of clusters that each contains related topics are identified (e.g., 100 responses may be grouped into 10 clusters). These clusters can then be used to define Breakouts and/or serve as a basis for Roundtable discussions.

Planning Meeting Logistics. Logistics for the Planning meeting are often developed during weekly teleconferences. Specific tasks for the PRG Leadership Team and sponsoring agency staff are outlined in **Table 2**.

Table 2. Planning Meeting Preparations

| Participant | Roles/Reponsibilities |
|-----------------|--|
| | Review prior Planning and Roundtable meeting agendas. |
| PRG Leadership | Prepare Planning meeting agenda (Figure 2). |
| Team | Propose approaches to encourage Planning meeting discussions. |
| | Prepare options for organization of the PRG Report. |
| | Work as a partner with Leadership Team. |
| | Provide guidance to Leadership Team. |
| | Update website, if available. |
| Sponsoring | Prepare current research, needs, and gaps analysis reports. |
| Agency Staff | Create presentation summarizing current state of the field. |
| | Track PRG participant recruitment. |
| | Provide logistical support. (Contractors may be used to assist in this effort.) |
| | Send invitation letters, logistics, and other pertinent information to PRG participants. |

Hold PRG Planning Meeting

The PRG Planning meeting is the first meeting of the sponsoring agency and PRG members (see **Figure 2** for sample agenda). The primary goal is to cooperatively design the Roundtable meeting. During the Planning meeting, the PRG develops methods for identifying recommendations and achieving consensus. Usually, both Breakout and consensus sessions are built into a Roundtable meeting. Specific roles and responsibilities are provided in **Table 3**.

During the Planning meeting, PRG members design Breakouts for the approximately 100 attendees at the Roundtable meeting (Figure 2). Breakouts provide an opportunity for small focused groups of 8 to 10 scientific and advocacy experts to discuss critical research issues

| | PRG Planning Meeting Age | nda |
|------------|--|---------------------------------|
| Day 1 | | |
| 5:30 p.m. | Dinner | |
| 6:45 p.m. | Welcome/Introductions | PRG Co-Chair |
| 7:00 p.m. | Sonsoring Agency's Commitment & Role in Eliminating the Target Disease | Sponsoring Agency Director |
| | Charge to the PRG: The Role of the PRG | PRG Executive Director |
| | Current Context | PRG Leadership Team |
| | - What We Know–State of the Science | |
| 0.00 | - Summary of Current Research, Needs, & Gaps Analyses Docum | |
| 8:20 p.m. | Preparation for the Next Day | PRG Co-Chair |
| 8:30 p.m. | Adjourn | |
| Day 2 | | |
| 7:00 a.m. | Breakfast | |
| 8:00 a.m. | Review & Discussion of Current Research Needs & Gaps Analyses Documents | PRG Leadership Team |
| 9:00 a.m. | Determine Roundtable Breakouts | PRG |
| 10:30 a.m. | Break | |
| 11:00 a.m. | Identify Breakout Co-Chairs | PRG |
| 12:45 p.m. | Lunch | |
| 2:00 p.m. | Select Breakout Participants | Small Groups |
| 3:15 p.m. | Draft Breakout Agenda | Breakout Co-Chairs/Small Groups |
| 3:45 p.m. | Draft Overall Roundtable Agenda | PRG Co-Chair |
| 4:00 p.m. | Review of Action Items/Closing Comments | PRG Leadership Team |
| 4:15 p.m. | Adjourn | |

Figure 2. Sample Planning Meeting Agenda

around a specific topic in the disease focus area. Breakouts should be designed in a manner that will lead to the development of a limited number (typically three) of high-quality recommendations that address the PRG charge (see sample charge on page 2). After Breakouts have been designed, PRG members agree on a strategy for developing a consensus list of approximately 10 overall recommendations.

miniating the

Table 3. Planning Meeting Roles/Responsibilities

| Participant | Roles/Reponsibilities |
|-------------------------|---|
| PRG Leadership | Present current state of the field. |
| Team | Facilitate the meeting. |
| PRG Participants | Design Roundtable meeting - Identify Breakout topics - Nominate Roundtable participants - Identify 2 to 3 Breakout Co-Chairs (at least 1 PRG and 1 non-PRG member) for each Breakout - Draft Roundtable meeting and Breakout agendas. |
| | Draft PRG Report's organization/outline. Agree upon strategy for reaching consensus and identifying and prioritizing key recommendations. |
| Spansaring | Provide insight on overall PRG process. |
| Sponsoring Agency Staff | Offer guidance and direction for specific components. |
| | Coordinate meeting and logistics. |

The PRG is usually given latitude in the design of Breakouts. The sponsoring agency staff provides the PRG with general guidance, such as time limits and examples of Breakout topics used by other PRGs. Breakouts can focus on specific scientific areas (e.g., biology and treatment) or disease topics (e.g., childhood forms of the disease and special issues of the elderly) and may be further subdivided for more in-depth discussions.

Roundtable participants are nominated based on their expertise in the context of the identified Breakouts. The criteria used to select Roundtable participants are similar to those used for PRG members (see page 6). A comprehensive and diverse composition for this group ensures that all research areas, initiatives, and issues will be considered. A list of potential Roundtable participants is compiled and prioritized. Eighty to 100 individuals should be selected and assigned to the specific Roundtable Breakouts. Two to three Co-Chairs, including at least one PRG member and one non-PRG member, are identified to lead each Breakout. The Roundtable meeting and Breakout agendas are drafted, and the organization of the PRG Report is established.

Prepare for Roundtable Meeting

Roundtable Preparation Tips

- → Prepare advocates and science writers for their roles at the Roundtable meeting.
- → Provide Breakout Co-Chairs and science writers with sample reports, templates for preparing Breakout reports, and templates for slides to present Breakout recommendations.
- → Ask Breakout Co-Chairs to draft background information/current state of knowledge in their Breakout topics before the Roundtable meeting.

This part of the Recommendation Phase is typically marked by periods of intensive work as the PRG Leadership Team, PRG members, and sponsoring agency staff prepare for the Roundtable meeting. Specific tasks to be accomplished include finalizing the agenda(s) and report formats, inviting Roundtable participants, confirming non-PRG Breakout Co-Chairs, preparing science writers and advocates and addressing meeting logistics (e.g., hotel, travel, and reimbursement). The roles and responsibilities for this stage are summarized in **Table 4**.

<u> Hold Roundtable Meeting</u>

Roundtable Meeting Goals

- → Discuss current knowledge and identify gaps.
- → Develop recommendations to fill gaps.
- Consolidate overlapping recommendations identified by Breakouts.
- → Build consensus around the recommendations.
- → Identify approximately 10 consensus recommendations on which to focus in the report.
- → Draft Breakout reports.
- → Outline main PRG Report.

The Roundtable meeting provides a forum to discuss the current state of knowledge, identify gaps in efforts, and develop and prioritize scientific recommendations that will advance the field (see sample Agenda, **Figure 3**). The roles and responsibilities for this meeting are summarized in **Table 5**.

The Roundtable meeting may include opening and closing plenary sessions for all participants before and after the Breakouts. In the opening session, participants can be oriented to the meeting process and informed about the current state of scientific knowledge concerning the disease focus so that they enter the Breakouts equally and fully informed.

During the Breakout sessions, participants engage in detailed discussions related to their Breakout topics and identify a set number (usually three) of Breakout recommendations. Breakout participants should identify new or existing resources for implementing each recommendation, as well as barriers. Their recommendations can be informed by analyses of the sponsoring agency's current research, needs, and gaps reports (see pages 6 and 7 for possible types of analyses). After the Breakouts groups have completed their deliberations, the Breakout Co-Chairs and science writers prepare presentations for

WORKING DRAFT

Table 4. Roundtable Meeting Preparations

| Participant | Roles/Reponsibilities |
|----------------------------|--|
| | Assist PRG members and Breakout Co-Chairs in inviting Breakout participants. |
| PRG Leadership | Finalize Roundtable meeting agenda (Figure 3). |
| Team | Prepare presentation(s) on current state of the field and current research, gaps, and needs analyses. |
| | Contact and confirm non-PRG Roundtable participants, including non-PRG Co-Chairs. |
| PRG Breakout | Finalize Breakout agendas and distribute to Breakout participants. |
| Co-Chairs | Prepare draft background/current state-of-knowledge section of the Breakout reports. |
| Roundtable Scientists | Review meeting support information (e.g., travel information; current research, needs, and gaps reports; and background information prepared by Co-Chairs). |
| Roundtable | Review meeting support information (e.g., travel information; current research, needs, and gaps reports; and background information prepared by Co-Chairs). |
| Advocates | Contact Breakout Co-Chairs with questions. |
| | Attend pre-Roundtable teleconference and orientation, if offered. |
| | Work with Leadership Team, Breakout Co-Chairs, Roundtable participants, and lead science writers to complete all pre-meeting tasks. |
| | Coordinate and facilitate teleconferences and other planning activities, (e.g., advocate and Leadership Team teleconferences). |
| Sponsoring Agency Staff | Send official correspondence and other meeting support information. (e.g., travel information; current research, needs, and gaps reports; and background information prepared by Co-Chairs). |
| | Secure 10 to 18 science writers (at least one science writer is assigned to each Breakout), including 1-2 lead writers. |
| | Hold teleconference with science writers to discuss process and expected product(s). |
| | Check for potential conflicts of interest among participants who will be making recommendations. |
| | Participate in pre-Roundtable science writer teleconference. |
| Science Writers | Review relevant background literature, previous PRG reports, and templates and software to be used at the meeting. |

| | PRG Roundtable Meeting Agenda | 1 |
|------------|---|---|
| Day 1 | | |
| 3:00 p.m. | Pre-Meeting Planning Sessions (Concurrent) - Leadership Pre-Meeting - Advocates Meeting - Science Writers Meeting | |
| 4:00 p.m. | Pre-Meeting Breakout Co-Chair Session | PRG Leadership Team |
| 5:00 p.m. | Dinner | |
| 6:30 p.m. | Welcome/Introductions/Charge to the PRG & Roundtable Participants Sponsoring Agency's Commitment & Role in Eliminating the Target Disease Current Context - What We Know-State of the Science - Summary of Current Research, Needs, & Gaps Analyses Documents | PRG Co-Chair Sponsoring Agency Director PRG Leadership Team |
| 8:20 p.m. | Preparation for the Next Day | PRG Co-Chair |
| 8:30 p.m. | Adjourn | |
| Day 2 | | |
| 7:00 a.m. | Breakfast | |
| 8:00 a.m. | Plenary - Overview of Breakouts | PRG Co-Chair |
| 8:15 a.m. | Concurrent Science-Centric Breakouts - Prevention - Etiology - Biology - Detection, Diagnosis, & Prognosis - Clinical Studies - Communication & Outcomes | |
| 11:45 a.m. | Lunch | |
| 1:00 p.m. | Plenary Session: Science-Centric Breakout Presentations (15 min. each) | Breakout Co-Chairs |
| 2:30 p.m. | Break | |
| 3:00 p.m. | Concurrent Cross-Cutting Breakouts - Training & Education - New Targets for Development & Therapy - Optimizing Existing Care - Partnership Platforms - Scientific Models | |
| 6:00 p.m. | Adjourn for Dinner | |
| 7:30 p.m. | Note: Co-Chairs & Science Writers Meet after dinner to draft Breakout Rep | ports |
| Day 3 | | |
| 7:00 a.m. | Breakfast | |
| 8:00 a.m. | Plenary Session: Cross-Cutting Breakout Presentations (15 min. each) | Breakout Co-Chairs |
| 9:15 a.m. | Prioritize Recommendations | All Participants |
| 10:00 a.m. | Break | |
| 10:15 a.m. | Prioritization Discussions Continue | All Participants |
| 12:15 p.m. | Next Steps & Closing | PRG Co-Chai |
| 12:30 p.m. | Roundtable Adjourns | |
| 12:30 p.m. | Lunch for PRG Members, Breakout Co-Chairs, Science Writers, & Suppor | t Staff |
| 1:30 p.m. | Breakout Co-Chairs and PRG Writing Session | Breakout Co-Chairs & PRG |
| 4:00 p.m. | Draft Breakout Reports Submitted | |

Figure 3. Sample Roundtable Meeting Agenda

Table 5. Roundtable Meeting Roles/Responsibilities

| Participant | Roles/Reponsibilities |
|---------------------------|--|
| | Facilitate Roundtable meeting discussions. |
| | Provide an overview and orientation for all meeting participants. |
| PRG Leadership | Provide oversight and guidance for breakouts. |
| Team | Lead development and prioritization of key recommendations and resources. |
| | Build consensus around priority recommendations and resources. |
| | Outline main PRG Report. |
| | Facilitate Breakout sessions. |
| | Provide input regarding key scientific questions. |
| PRG Breakout Co-Chairs | Achieve consensus on Breakout recommendations and resources. |
| GO-Glialis | Draft Breakout reports. |
| | Present Breakout group's recommendations to all Roundtable participants. |
| Roundtable | Offer consumer, patient, advocacy, and family member perspectives. |
| Advocates | Identify key questions and barriers. |
| Downskable | Offer current state of scientific knowledge and identification of gaps. |
| Roundtable Scientists | Identify key scientific questions and barriers for potential recommendations. |
| | Suggest resources for implementing each recommendation. |
| Science Writers | Record discussions and decisions. |
| | Assist Breakout Co-Chairs in preparing draft Breakout reports and presentations. |
| | Provide oversight and logistic support for Roundtable meeting. |
| Sponsoring | Provide oversight for development of Breakout reports. |
| Agency Staff | Obtain signed conflict of interest forms from all participants that do not work for the sponsoring agency. |

the plenary session, as well as draft Breakout reports with a back-ground/current state-of-knowledge section (prepared by the Co-Chairs in advance of the meeting) and the group's recommendations, resources, and barriers.

Each Breakout group then presents its recommendations to all Roundtable participants. Using a strategy agreed upon during the Planning meeting, the Roundtable participants can then prioritize the Breakout recommendations and select the final list of approximately 10 recommendations to highlight in the PRG Report.

Roundtable Meeting Tips

Breakouts

- → Ask Co-Chairs to prepare background summary for Breakout Report prior to meeting. Solicit input from Breakout participants on the background and summary that was prepared by the Breakout Co-Chairs.
- → Encourage participants to limit the number of recommendations per breakout to no more than three.
- → Construct clear and specific recommendations.
- → To assist in reaching a consensus, use a projection system to display recommendations to the entire room.

Coordination among Breakouts

- → Have PRG Leadership Team and sponsoring agency leadership visit all Breakout sessions, providing facilitation as needed.
- → Prior to the start of Breakout sessions, hold a dedicated session for advocates to provide additional guidance and support.

Roundtable Consensus Recommendations

- → Hold a closing consensus session for all attendees to discuss priority recommendations. Complete presentation templates that outline similiar summary information for each Breakout.
- → Focus on specific, clear recommendations instead of numerous overlapping, vague recommendations.
- → Limit the number of PRG priority recommendations to approximately 10.

Reports

- → Collect all drafts of Breakout reports before PRG members depart.
- → Draft an outline for the main PRG Report.
- → Capture Breakout discussions for incorporation in the final PRG Report.

Signatures

- → Collect signatures from PRG members for use on concurrence page in final PRG Report. (Note this can also be done during the Planning Meeting.)
- → Collect signed Conflict of Interest form after opening session, ensure all forms are correctly filled out, and any potential conflicts are addressed early in the meeting.

Prepare PRG Report

The PRG Report provides an overview of the state of the science; outlines top research priorities, resources, and barriers for a given disease or group of diseases; and serves as a benchmark from which progress can be assessed. The report reflects the opinions of approximately 100 individuals who have a vested interest in the nation's future research on the targeted disease. A key element of this report is the list of consensus recommendations that will help advance future research. Examples of PRG Report tables of contents are shown in **Figure 4**. In addition, reports from NCI-sponsored PRGs are posted on the Web (http://prg.nci.nih.gov/).

The PRG Leadership Team, with the support of the lead science writers and sponsoring agency staff, is responsible for the overall

development and content of the report. With support from science writers and sponsoring agency staff, Breakout Co-Chairs are responsible for reviewing and coordinating comments from their group members, and preparing their Breakout reports. Each PRG member is given an opportunity to review, comment on, and approve the PRG Report. Finally, concurrence of all PRG members with the content of the PRG Report can be shown by including their signatures in the report.

Present Key Findings to Agency Leaders and Release Report

The PRG Leadership Team may summarize the findings and priority recommendations of the report and present them to the sponsoring agency's Director and senior leadership for suggestions and acceptance. Upon acceptance, the PRG Report is published in electronic and print format and widely disseminated. Posting the electronic version on the website immediately upon approval facilitates public access until the print version is available.

| | 1 | |
|--|--|--|
| Sample 1 Table of Contents From the PRG | 3 9 0 1 1 2 13 13 App App | From the PRG Introduction Scope of the Property PRG Charge State of the Science Opportunities for S Challenges to Be Action PRG Consensus Discovery Translational Retreatment Control Infrastructure Infrastructure Opendix 1: Breakout the Bendix 2: About the Bendix 3: PRG Memendix 4: Roundtable |

| Cor App App | Sample 2 Table of Contents From the PRG Introduction 4 Scope of the Problem 5 PRG Charge 5 State of the Science 7 Opportunities for Scientific Advancements 8 Challenges to Be Addressed 8 Ten PRG Consensus Recommendations 9 Discovery 9 Translational Research 10 Treatment 10 Control 10 Infrastructure 11 Inclusion 11 Dendix 1: Breakout Reports 12 Pendix 2: About the Sponsoring Agency's PRS 1-1 |
|-------------------|---|
| יףף | endix 3: PRC Manual Proposition Agency's PRG |
| | endix 4: Roundtable Participant Roster |
| | |

Figure 4. Sample Tables of Contents for PRG Reports*

*Sample NCI PRG Reports can be found at: http://prg.nci.nih.gov.

PHASE II

The Implementation Phase

The purpose of the Implementation Phase is to develop strategies that the sponsoring agency will use to address the recommendations outlined in the PRG Report. This assessment is used to identify potential gaps and serves as a platform for developing an Implementation Strategy that outlines how the sponsoring agency can address the PRG recommendations. During this phase, a Response meeting provides a forum for the sponsoring agency and the PRG members to discuss strategies that are being considered for the Implementation Strategy. The tasks for this phase, the participants' responsibilities, and the projected timeline are given in **Table 6**.

Table 6. Implementation Phase Tasks, Participants' Responsibilities, and Timeline

| Task | Sponsoring Agency Staff | Working Group | PRG Members | Sponsoring Agency Director | Approximate Duration |
|---|-------------------------------|------------------|----------------|----------------------------------|-------------------------|
| Establish internal Working Group. | ✓ | | | | < 1 month |
| Map agency's initiatives and projects to PRG recommendations. | ✓ | V | | | 2 to 3 months |
| Prepare proposal for implementing PRG recommendations. | V | V | | | 4 to 6 months |
| Hold Pre-Response meeting. | ✓ | ✓ | | V | 1/2 day |
| Hold Response meeting. | ✓ | ✓ | ✓ | V | 1/2 day |
| Prepare and promote Implementation Strategy. | V | V | · | V | 3 to 4 months |
| Identify measures of progress. | ✓ | | | | 2 to 3 months |

Establish Internal Working Group

A group of approximately 7 to 10 disease-specific experts from within the sponsoring agency is established to develop an Implementation Strategy. Members of this Working Group should be able to address the scientific issues within the PRG Report and understand and be familiar with the agency's research portfolio. Working Group members should represent multiple scientific divisions and departments

within the agency, work well on a team, and have the time to perform tasks associated with the Implementation Phase. In addition, it is helpful for the Executive Director of the PRG and/or other agency staff that served on the PRG to also join the Working Group. This phase will be marked by periods of concentrated effort.

Map Agency's Initiatives and Projects to PRG Recommendations

The Working Group begins the Implementation Phase by reviewing the PRG Report and mapping the agency's existing initiatives, activities, resources, and funded projects to the PRG recommendations. The end product is a Mapping Document listing sponsoring agency initiatives and projects addressing the PRG recommendations. A Mapping Document can be prepared in outline form with major headings for each PRG recommendation and subheadings for current and planned research activities. It is used to identify both strengths and gaps in the agency's activities and can serve as the baseline for reporting progress in Phase III.

Mapping Document

Information that can be provided for every PRG recommendation includes:

- → Directly Relevant Initiatives
 - List of Requests for Applications (RFAs) and Program Announcements (PAs) that address recommendation
 - Number of projects funded, both total and disease specific, for each listed RFA/PA
 - Titles of funded disease-specific projects
- → Potentially Relevant Initiatives
 - List of relevant RFAs/PAs
 - Number of projects funded
 - Titles of funded disease-specific projects
- → Planned Initiatives
 - Summary description of initiatives in sponsoring agency's current plan and budget proposal that could address the PRG recommendation
- → Relevant Resources
 - List of sponsoring agency-supported resources, e.g., tissue banks and gene databases
- → Other Relevant Projects
 - Titles of projects supported by the sponsoring agency that were not solicited through an RFA/PA listed in other sections of the mapping document, e.g., investigator-initiated projects



Prepare Proposal for Implementing PRG Recommendations

Upon review of the Mapping Document, the Working Group develops a Proposed Strategies to Address Gaps and Needs document. Like the Mapping Document, this proposal is divided into sections that align with each PRG recommendation. It can contain additional details on each recommendation, current agency activities, and proposed strategies. The proposed strategies are designed to fill gaps and needs that are not being addressed by current agency-supported activities and initiatives. These strategies should help expedite progress in each of the areas identified by the PRG.



Proposed Strategies to Address Gaps and Needs Document

Information that can be provided for every PRG recommendation includes:

- → Research Issues/Rationale Excerpts from the PRG Report that support the recommendation.
- → Current Activity Analysis Summation of lists included in the Mapping Document.
- → Recommended Position A brief summation of the Working Group's strategies for future investments.
- → Suggested Strategies
 - In Process/Planned A list and brief description of activities that are/may be supported by the sponsoring agency. This includes both ongoing and new initiatives proposed in the agency's most recent budget.
 - Newly Proposed A list and brief description of activities that are not yet included in any current or proposed budgets.

Pre-Response Meeting

The purpose of the Pre-Response meeting is for the Working Group to discuss the proposed strategies with the sponsoring agency's Director. During the Pre-Response meeting, the Director advises the Working Group on a preferred strategic approach, commenting on which proposed strategies can be publicly presented. The Working Group then revises the proposal to reflect the Director's guidance and prepares for the Response meeting.

Response Meeting

To prepare for the Response meeting, PRG members are sent the Mapping Document and a truncated form of the Proposed Strategies to Address Gaps and Needs document (see previous sections for descriptions of these documents) containing only the research issues/rationale and current activity analysis subsections.



During the Response meeting, the sponsoring agency leaders, the Working Group, and the PRG review the agency's current activities and proposed strategies for implementing the PRG recommendations. The strategies that were agreed on by the sponsoring agency during the Pre-Response meeting can be presented to the PRG by a Working Group member. In addition PRG members may also suggest additional strategies during the meeting. The entire group then discusses the most important strategies for implementing the PRG recommendations and come to a consensus on key implementation strategies. The roles and responsibilities for the meeting are summarized in **Table 7**.

Table 7. Response Meeting Roles/Responsibilities

| Participant | Roles/Reponsibilities | | |
|-----------------------------|--|--|--|
| Sponsoring | For each recommendation, identify current sponsoring agency activities and gaps. | | |
| Agency Leaders, | Present proposed strategies to address PRG recommendations. | | |
| Staff, and Working Group | Assess additional strategies presented by the PRG. | | |
| working Group | Discuss and select key strategies. | | |
| | Review current sponsoring agency activities and gaps. | | |
| PRG Members | As needed, identify additional strategies for addressing PRG recommendations. | | |
| | Assess strategies proposed by Working Group. | | |

Prepare and Promote Implementation Strategy

The Working Group uses the list of proposed strategies presented during the Response meeting and incorporates modifications to reflect PRG recommendations as the basis for building the Implementation Strategy. For each strategy, the Working Group determines cost, feasibility, available infrastructure, potential impact, and opportunities for partnerships within and outside the agency. To identify

Criteria Used for Prioritizing Strategies

The Implementation Strategy document highlights existing and proposed strategies that the sponsoring agency will support. Factors that can be considered when prioritizing strategies include:

- → Does the strategy address the highest priority needs and gaps identified by the PRG?
- → Does the strategy build on existing initiatives and leverage existing mechanisms?
- → Is the strategy feasible to execute, e.g., based on cost, availability of staff to coordinate, and availability of expertise?
- → Does the strategy have the potential to result in a significant return on investment?
- → Is the strategy adequately developed?
- → Is the strategy new and not overlapping with other initiatives both within and outside the sponsoring agency?



which strategies should be incorporated into the Implementation Strategy, criteria (such as those listed previously) can be established to compare strategies. As illustrated in **Table 8**, a categorization scheme may then be set up for organizing strategies and activities in the Implementation Strategy.

The Working Group drafts a comprehensive Implementation Strategy detailing agency strategies to hasten progress. The draft plan is usually presented to the sponsoring agency's Director and other high-ranking officials to determine which strategies will be adopted and implemented. The report is revised as needed and prepared for public information, publication, and dissemination. The Implementation Strategy may be available in electronic and print forms. In addition, NCI Strategic Plans can be found on the Web (http://prg.nci.nih.gov/).

Table 8. Potential Implementation Strategy Scheme

| Activity/Strategy | Description | | |
|-----------------------|---|--|--|
| Ongoing Activities | Initiatives that are currently supported by the agency. | | |
| New Activities | Initiatives that the agency has started within the past year. | | |
| Immediate Strategies | Initiatives that the agency has started to implement. | | |
| Short-Term Strategies | Initiatives that the agency is currently developing as a first step toward implementation. (Actual implementation may depend upon availability of funds and a final determination that the strategy is feasible and scientifically sound.) | | |
| Mid-Term Strategies | Initiatives that the agency will further develop over the next several months. | | |
| Long-Term Strategies | Important strategies that the agency will not be able to implement in the near future. | | |

Identify Measures of Progress

The final task for the Working Group is to identify qualitative/ quantitative measures to track and monitor progress on PRG recommendations and activities outlined in the Implementation Strategy. These measures should include both short- and long-term milestones. If appropriate, monitoring systems may be established that could include progress reports or meetings.

In addition, the sponsoring agency may establish a database and system to track and quantify research activities and accomplishments. For example, a database may be used to categorize individual projects according to which PRG recommendations they address. Publications, patents, and research findings that result from agency-supported projects may also be tracked in a database.

PHASE III

The Reporting Phase

The purpose of the Reporting Phase, which take place a few years after the Implementation Phase, is to assess progress since the PRG Report was published. This process involves review and analysis by the sponsoring agency staff and the Working Group of initiatives and projects that supported research on the targeted disease. The results from this assessment are incorporated into a progress report. The tasks for this phase, the participants' responsibilities, and the projected timeline are depicted in **Table 9**.

Table 9. Reporting Phase Tasks, Participants' Responsibilities, and Timeline

| Task | Sponsoring Agency Staff | Working Group | PRG Members | Approximate Duration |
|--|-------------------------------|------------------|----------------|-------------------------|
| Reconvene Working Group. | ✓ | | | 1 month |
| Collect and analyze data. | ✓ | ✓ | | 3 to 10 months* |
| Prepare progress report. | ✓ | ✓ | | 2 to 4 months* |
| Discuss progress with sponsoring agency leaders and advisors | ✓ | ✓ | | 1 to 2 months |
| Reconvene PRG and hold a PRG meeting (optiona | l). 🗸 | ✓ | V | 1 to 2 months* |
| Refine Implementation Strategy. | ✓ | ✓ | ~ | 1 to 2 months |

^{*}Overlapping activities.

Reconvene Working Group

Three to 4 years after the publication of the Implementation Strategy, the Reporting Phase is initiated by reconvening the Working Group. The agency may augment the initial Working Group members with additional members who bring scientific expertise in areas that have been very active over recent years. For example, during the Implementation Phase, one member of the Working Group may represent basic biology. However, if biology has been a very active research area, it may be necessary to add additional members with this expertise to the Working Group.

Collect and Analyze Data



Collecting and analyzing data are the steps that will require the majority of time in the Reporting Phase. However, while these require the most effort, they do not have to be completed before beginning to write the report. In general, measures of progress can be categorized into four groups: standard metrics used to assess research progress, number of projects responsive to PRG recommendations, initiatives implemented as result of the Implementation Strategy, and research accomplishments.

- Standard metrics include measures that are commonly viewed by the scientific community as markers of progress. These can include numbers of publications, patents, and clinical trials, funding, and disease statistics. Data can be analyzed over time and presented as counts per year from a few years preceding the PRG Report to the present.
- The sponsoring agency's responsiveness to PRG recommendations can be gauged in part by the number of projects addressing each recommendation. During the Implementation Phase, ongoing projects were mapped to each PRG recommendation to establish baseline support and identify gaps. Projects supported since the publication of the PRG Report can be mapped to each recommendation and the number of these projects can be compared to baseline data.
- The Implementation Strategy outlined ongoing, new, and proposed initiatives that could address PRG recommendations. Details on the status of these initiatives and resulting research projects and findings can be assessed.
- Research accomplishments can be quite extensive, and it would be difficult to develop a comprehensive list of accomplishments that cover research results for a specific disease. However, examples can be collected that cite particularly exciting, novel, or emerging areas of investigation. These examples can be used to illustrate progress and complement the statistics reported for the previous three measures of progress.

Prepare Progress Report

The sponsoring agency staff, with the support and guidance of the Working Group, prepares a Progress Report. The goals of the report are to provide a synopsis of progress over the previous 3 to 5 years and to report on agency actions in response to PRG recommendations and the Implementation Strategy. Since the Progress Report, in part, provides a forum for accountability and communication, both positive and negative trends should be included. (See **Figure 5** for a sample Table of Contents or completed NCI progress reports can be found at: http://prg.nci.nih.gov.)

Discuss Progress with Sponsoring Agency Leaders and Advisors

The Progress Report can be used by as a basis for experts to discuss progress made by the sponsoring agency. These experts can be from within the agency or they can be a group of external advisors, e.g., a reconstituted PRG (see below). Based on the advice of experts, the sponsoring agency may make course corrections, as needed.

Reconvene PRG and Hold a PRG Meeting (optional)

A 20- to 30-member PRG can be reconstituted for the purpose of reviewing the Progress Report, discussing progress with sponsoring agency staff, and recommending adjustments in current and future implementation strategies. As with the original PRG, members represent the scientific, medical, and advocacy communities, as well as the private sector. Consideration is given to adequate disciplinary, institutional, geographic, gender, and ethnic representation. If available, members of the original Leadership Team can be invited to coordinate work for the reconstituted PRG. The reconstituted PRG may contain a combination of individuals from the original panel and new members.

A PRG meeting can be held to provide an opportunity for the sponsoring agency to discuss progress with experts in the field. Based upon the Progress Report, the PRG can discuss (1) measures of progress, (2) how well the agency has addressed recommendations developed in Phase I, and (3) continuing and new gaps in the research portfolio. The PRG may suggest revising, or retiring, recommendations and strategies that were instituted through Phases I and II or developing new ones.

| Progress Report Table of Contents | |
|--|-----|
| Transmittal Letter | i |
| Acknowledgments | |
| Executive Summary | |
| Chapter 1 - Research on Disease Focus: 2000-2004 | |
| The Disease Burden | |
| The Progress Review Group | |
| Five Years of Progress | |
| Clinical Trials Supported | |
| Initiatives Undertaken | |
| Resources Developed or Maintained | |
| Programs Established or Expanded | |
| Research Results Obtained and Applied | |
| Looking to the Future | 10 |
| Chapter 2 - Initiatives Chapter 3 - Investment and Response | 17 |
| Sponsoring Agency's Investment and Response | |
| Chapter 3 - Biology: Investment and Recent Progress | |
| Sponsoring Agency's Investment and Responsiveness | 29 |
| Ongoing Research by the Sponsoring Agency: Recent Progress | |
| Continuing Needs and Evolution | |
| Future Investment in Biology | 36 |
| Chapter 4 - Etiology and Prevention: Investment and Recent Progress | |
| Sponsoring Agency's Investment and Responsiveness | |
| Ongoing Research by the Sponsoring Agency: Recent Progress Continuing Needs and Evolution | |
| Future Investment in Etiology and Prevention | |
| Chapter 5 - Detection, Diagnosis, and Prognosis: Investment and Recent Progress | |
| Sponsoring Agency's Investment and Responsiveness | 43 |
| Ongoing Research by the Sponsoring Agency: Recent Progress | 44 |
| Continuing Needs and Evolution | |
| Future Investment in Detection, Diagnosis, and Prognosis | 48 |
| Chapter 6 - Treatment: Investment and Recent Progress | 40 |
| Sponsoring Agency's Investment and Responsiveness Ongoing Research by the Sponsoring Agency: Recent Progress | |
| O R T M I TE LE | 55 |
| Future Investment in Treatment | |
| Chapter 7 - Control, Survivorship, and Outcomes: Investment and Recent Progress | |
| Sponsoring Agency's Investment and Responsiveness | 57 |
| Ongoing Research by the Sponsoring Agency: Recent Progress | |
| Continuing Needs and Evolution | 61 |
| Future Investment in Control, Survivorship, and Outcomes | |
| Appendix A - References | |
| Appendix B - Working Group Membership Roster | B-1 |
| Appendix C - Research Projects Supported by Sponsoring Agency and Relevant to the Disease Focus That Were Active in 2004 | C-1 |
| Appendix D - U.S. Patents Resulting from Research on the Disease Focus and | |
| Supported by Sponsoring Agency: 2000-2004 | D-1 |

Figure 5. Sample Progress Report Table of Contents

Refine Implementation Strategy

Based upon the Progress Report, the sponsoring agency may revise the Implementation Strategy. The format of this update will depend upon the issues related to the disease and the extent of change since the PRG was first convened and the Implementation Strategy was developed.

This final step addresses the overall goal of the PRG process: To provide a vehicle through which an agency can chart a course to hasten progress. This course may be different from the one established 3 to 4 years earlier. However, this flexibility provides a means to adapt to changing and emerging needs.

Conclusion

The PRG process can help agencies sustain high-quality science, address emergent needs, and make appropriate course corrections for prioritizing their research investments. A PRG can assist in shaping research directions by providing an agency with guidance on research priorities, gaps, and resources that are needed to advance research on a targeted disease. Based upon the guidance provided by a PRG, a sponsoring agency can develop an Implementation Strategy to address these priorities. Through continued communication and appropriate course corrections, the agency can respond and adjust their plan to address the fast-paced flow of new and emerging research needs.

Conclusion 26